Strata Critical Medical Announces Third Quarter 2026 Results
Key Highlights
- ➤Revenue $74.1 million, up 50.3% year-over-year in Q3 2026
- ➤Adjusted EBITDA $9.6 million, up 128.0%, with 13.0% margin
- ➤Clinical revenue $29.2 million, up 20.3% sequentially, driven by acquisitions
- ➤$20 million share repurchase authorization announced alongside continued M&A
- ➤2026 guidance reiterated: revenue $285-295 million, Adjusted EBITDA $33-35 million
Expert Statements
Melissa Tomkiel, Co-CEO and General Counsel of Strata Critical Medical
“Our strong third quarter results speak for themselves”
Melissa Tomkiel, Co-CEO and General Counsel of Strata Critical Medical
“We demonstrated additional market share gains in our clinical business, continued sequential margin improvement, and a reduction in our Adjusted SG&A base quarter-over-quarter, even following our significant growth and the completion of three acquisitions during Q2.”
Melissa Tomkiel, Co-CEO and General Counsel of Strata Critical Medical
“Strategically, this quarter puts a spotlight on the scalability and cash generation potential of our business model with a record $8.6 million of Free Cash Flow in Q3.”
Melissa Tomkiel, Co-CEO and General Counsel of Strata Critical Medical
“Tactically, we are happy to see Logistics gross margins back up above our 20% target faster than we anticipated.”
Will Heyburn, Co-CEO and CFO of Strata Critical Medical
“Given Strata's improved cash generation coupled with the receipt of our first passenger sale earn-out, we are now in a position to both accelerate our target pace of acquisitions as well as opportunistically return cash to shareholders through our new buyback program”
Will Heyburn, Co-CEO and CFO of Strata Critical Medical
“We have an excellent pipeline of opportunities to deploy capital at mid-single-digit cash flow multiples with a focus on opportunities that will further enhance our overall margin and free cash conversion profile.”
Will Heyburn, Co-CEO and CFO of Strata Critical Medical
“We are also pleased to report that we are pacing ahead of the medium-term goals we set out last year.”
Will Heyburn, Co-CEO and CFO of Strata Critical Medical
“The underlying driver of our financial performance is simple: better service, architected for efficiency, delivered in partnership with our customers to prioritize their individual preferences and our shared goal to save more lives.”
* Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 * Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 * Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenue * Adjusted EBITDA((1)) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0% * Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow((1)) was $8.6 million in Q3 2026 * Announced $20 million share repurchase authorization; will be deployed along with continued M&A strategy execution NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
GAAP FINANCIAL RESULTS (in thousands except percentages, unaudited)
Get started
Create a free account to read the full story.